Cardiff Oncology, Inc. Logo

Cardiff Oncology, Inc.

A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.

CRDF | US

Overview

Corporate Details

ISIN(s):
US14147L1089
LEI:
Country:
United States of America
Address:
11055 FLINTKOTE AVENUE, 92121 SAN DIEGO

Description

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2022-02-24 17:09
8-K
English ZIP 737.6 KB
2022-02-24 17:00
10-K
English ZIP 2.2 MB
2022-02-14 17:13 English ZIP 21.5 KB
2022-02-14 17:04
SC 13G/A
English ZIP 18.4 KB
2022-02-11 20:12 English ZIP 19.5 KB
2022-02-10 15:25
JANUS HENDERSON GROUP PLC OWNS >5%
English ZIP 12.4 KB
2022-02-09 13:06 English ZIP 9.6 KB
2022-02-04 17:12 English ZIP 13.4 KB
2022-01-31 18:29
8-K
English ZIP 723.1 KB
2022-01-18 18:00
8-K
English ZIP 4.9 MB
2022-01-14 14:34
FORM 3
English ZIP 6.7 KB
2022-01-11 11:09
8-K
English ZIP 721.2 KB
2021-12-10 12:14
8-K
English ZIP 709.6 KB
2021-12-03 12:05
8-K
English ZIP 565.4 KB
2021-11-18 11:52
424B5
English ZIP 420.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiff Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cardiff Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cardiff Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom affinity binders for research, diagnostics, and therapeutics.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
United States of America
APVO
Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
A product design and development firm providing services from concept to manufacturing.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
United States of America
ARVN
Asarina Pharma AB Logo
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
An integrated biologics development partner offering services from DNA sequence to cell bank.
South Korea
355690

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.